Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second clinical trial of ONS-5010 in the U.S. for the treatment of wet age related macular degeneration (wet AMD)

Trial Profile

Second clinical trial of ONS-5010 in the U.S. for the treatment of wet age related macular degeneration (wet AMD)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Outlook Therapeutics
  • Most Recent Events

    • 18 Dec 2018 According to an Outlook Therapeutics media release, if the companys wet AMD clinical program (two adequate and well controlled studies for wet AMD-CT profile 301711 and 301714) is successful, it will support the companys plans to submit for regulatory approval in multiple markets in 2020.
    • 20 Nov 2018 New trial record
    • 07 Nov 2018 According to an Oncobiologics media release, the U.S. portion of this study is scheduled to begin in early 2019 upon the submission of an investigational new drug (IND) application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top